SGLT2 Inhibitors following acute myocardial infarction: a systematic review and meta-analysis
Circulation; 150 (Suppl. 1), 2024
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits in various settings. However, their impact after myocardial infarction (MI) in patients without prior heart failure remains unclear. Therefore, we conducted a meta-analysis comparing SGLT2i to placebo...